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Since its introduction in the early 1970s [1], the technetium
dimercapto-succinic acid (Tc-DMSA) scan has been used as a
static imaging agent to detect cortical defects in the kidneys [2—7].
Scintigraphy provides an image of the functional renal paren-
chyma, and the renal uptake of Tc-DMSA has been shown to
correlate well with the effective renal plasma flow (ERPF),
glomerular filtration rate (GFR) and creatinine clearance [8—10].
Thus, the renal uptake of Tc-DMSA provides a practical index for
evaluation of individual renal function.
Measurement of the individual Tc-DMSA uptake by the kid-
neys has been described using planar and single photon emission
tomography (SPECT) techniques [9, 11—18]. Quantitative SPECT
of Tc-DMSA uptake by the kidneys (QDMSA) is a relatively
simple technique, easily standardized and allows determination of
individual and global renal function [12, 19]. In previous studies
QDMSA was useful in separating normal from diseased kidneys
[12]. Also, a good correlation was found between QDMSA and
renal function measured by creatinine clearance in patients with a
single kidney, validating the measurements in each kidney sepa-
rately [19]. In the present report the precision of the method was
evaluated to determine the reproducibility of QDMSA in the
same patient.
METHODS
Patient population
Fifteen volunteers (4 females and 11 males), mean age 45-
years-old (range 23- to 78-years-old), without known renal disease
and having normal serum creatinine, were studied by two sequen-
tial quantitative SPECT examinations with a mean interval of four
days apart (range 2 to 7 days). The studies were performed 4 to 6
hours after the intravenous injection of 2 mCi of the radiophar-
maceutical. The exact dose injected was obtained by measuring
the syringe in a dose calibrator before and after injection. Images
of the injection site was obtained to detect extravascular injection
of the radiopharmaceutical. Renal functional volume (cc), per-
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centage of injected dose per cc of renal tissue (%ID/cc) and
percent of individual renal uptake (%)of 30 normal kidneys were
studied.
Quantitative SPECT
Quantitative SPECT of DMSA uptake by the kidneys was
measured using the same methodology as in previous studies [12,
19]. The amount of radioactivity was corrected for decay from the
time of preparation to the time the study was actually performed.
The studies were performed using a rotating gamma camera and
an all-purpose, low energy collimator. Data acquisition lasted 20
minutes and required 120 projections (3° apart), and the entire
study accumulated 3 to 5 X i0 counts. Raw data were recon-
structed by filtered backprojection with a Hanning filter with a
cutoff point of 0.5 cycle/cm. Data were analyzed and stored on an
Elscint SP-1 computer with an optical disk. This 32-bit computer
utilized our software program for quantitative SPECT calcula-
tions. After reconstruction, each image was sectioned at I-pixel
(0.68 cm) intervals in the transaxial, coronal and sagittal planes
using a 64 x 64 byte matrix. Kidney volumes and radioactive
concentration measurements were calculated on the reconstruc-
tion data using the threshold method. A threshold of 43% has
been found to be highly reliable in a variety of phantoms and
human tissues [20]. The study required only 20 minutes, and data
analysis was practically automated and operator independent,
with very low intra- and interobserver variability [201. The method
does not deny that tissue attenuation is present hut assumes that
cancellation of attenuation effects occurs. Consideration of the
theoretical role of attenuation and the inability to correct for it
has led us to use the empirical threshold method and to demon-
strate its usefulness and reliability by extensive phantom studies
and by the only meaningful gold standard: the in vivolin vitro
correlation [20].
In brief, the operator chooses the slice to define the kidney and
draws a region of interest (ROl) around the organ. For volume
measurements (cc) the number of pixels in all sections multiplied
by the slice thickness is summed. For concentration measure-
ments, the threshold value was subtracted from all pixels in the
ROl in all slices. All the nonzero pixels that have higher counts
than the threshold value are used to calculate the concentration.
Counts per voxel are converted into concentration units (/LCi!cc)
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Table 1. Results of quantitative SPECT of DMSA uptake by the kidneys
Quantitative SPECT
First Second
Differences
lst-2nd
Kidneys Vol %ID Uptake Vol %ID Uptake Vol %ID Uptake Vol %ID Uptake
1 232 6.3 14.6 229 6.5 14.9 3.0 —0.2 —0.3 1.3 —3.1 —2.0
2 213 5.0 10.6 213 4.7 10.0 0.0 0.3 0.6 0.0 6.2 6.2
3 157 10.8 17.0 162 9.4 15.2 —5.0 1.4 1.7 —3.1 13.8 10.7
4 240 4.2 10.1 215 4.2 9.0 25.0 0.0 1.1 10.9 0.0 10.9
5 251 5.1 12.8 227 5.9 13.4 24.0 —0.8 —0.6 10.0 —14.5 —4.5
6 264 5.6 14.7 262 5.8 15.3 2.0 —0.2 —0.6 0.76 —3.5 —4.0
7 220 6.3 14.1 225 5.5 12.5 —5.0 0.8 1.6 —2.2 13.6 12.0
8 266 7.7 20.5 281 7.0 19.8 —15.0 0.7 0.7 —5.5 9.5 3.5
9 282 5.3 15.2 272 5.2 14.2 10.0 0.1 1.0 3.6 1.9 6.8
10 172 12.6 21.8 176 11.0 19.4 —4.0 1.6 2.4 —2.3 13.6 11.6
11 198 8.2 16.3 189 8.7 16.7 9.0 —0.5 —0.4 4.6 —5.9 —2.4
12 194 10.4 20.3 201 10.0 20.3 —7.0 0.4 0.0 —3.5 3.9 0.0
13 176 11.1 19.6 179 12.0 21.5 —3.0 —0.9 —1.9 —1.6 —7.8 —9.2
14 207 9.7 20.3 214 8.7 18.7 —7.0 1.0 1.6 —3.3 10.9 8.2
15 235 8.6 20.2 242 7.5 18.4 —7.0 1.1 1.8 —2.9 13.7 9.3
16 216 7.2 15.5 202 6.8 13.8 14.0 0.4 1.8 6.7 5.7 12.4
17 194 5.0 9.7 192 5.0 9.6 2.0 0.0 0.1 1.0 0.0 1.0
18 160 10.2 16.3 158 9.5 15.0 2.0 0.7 1.3 1.3 7.1 8.4
19 254 4.5 11.4 260 4.4 11.4 —6.0 0.1 0.0 —2.3 2.5 0.1
20 253 5.3 13.4 237 6.0 14.2 16.0 —0.7 —0.8 6.5 —12.4 —5.7
21 257 5.5 14.1 254 5.7 14.6 3.0 —0.2 —0.5 1.2 —3.6 —3.5
22 228 7.6 17.6 237 6.9 16.5 —9.0 0.7 1.1 —3.9 9.6 6.4
23 279 6.9 19.4 288 6.1 17.8 —9.0 0.8 1.6 —3.2 12.3 8.6
24 278 5.5 15.4 272 5.2 14.2 6.0 0.3 1.2 2.2 5.6 8.1
25 159 12.1 19.3 161 10.4 16.8 —2.0 1.7 2.5 —1.2 15.0 13.8
26 183 9.0 16.6 184 8.9 16.4 —1.0 0.1 0.2 —0.5 1.1 1.2
27 168 11.2 18.8 155 11.8 18.4 13.0 —0.6 0.4 8.0 —5.2 2.1
28 167 11.0 18.5 185 11.5 21.4 —18.6 —0.5 —2.9 —10.5 —4.4 —14.5
29 228 9.9 22.7 216 9.5 20.6 12.0 0.4 2.1 5.4 4.1 9.7
30 189 8.5 16.0 196 7.4 14.4 —7.0 1.1 1.6 —3.6 14.0 10.5
mean 217 7.9 16.4 216 7.6 15.8 1.2 0.3 0.6 0.4 3.4 3.8
SD 39 2.5 3.4 38.0 2.3 3.3 10.3 0.7 1.2 4.8 8.1 7.1
Abbreviations are: vol, volume; %ID, percent of injected dose per cc (X100); uptake, absolute kidney uptake (%);
%, difference between first and second study expressed as a % of the mean value of both studies.
using the regression line obtained previously by phantom mea-
surements. The percentage of injected dose per cc of renal tissue
(%IDIec) was calculated using this value corrected for radioactiv-
ity decay. Kidney uptake is then obtained by multiplying kidney
volume (cc) and %ID/ec.
Statistical analysis
Values are expressed by their mean I SD. For each pair of
quantitative SPECT determinations of volume, %ID/ce and up-
take, the difference between first and second studies and the least
square linear regression coefficient were determined. Also, the
difference between the first and second studies was expressed as a
percentage of the mean value of the two studies. The precision of
the method is represented by the SD of these differences [21].
RESULTS
Volume
The mean volume value was 217 cc 39 cc (range 157 cc to 282
cc) for the first study and 216 cc 38 cc (range 155 cc to 288 cc)
for the second study. A good correlation was found between first
and second studies (y = 0.94x + 11.0; r = 0.96). The mean
difference between first and second studies was 1.2 cc 10.3 cc
(range — 18cc to 25cc), and the mean difference between the first
lst-2nd, first minus second study;
and second studies as a percentage of the mean value of the two
studies was 0.46% 4.8 (range —10.5% to 10.9%). In 22 kidneys
the difference was less than 5%, in five kidneys it was between 5%
and 9.9%, and in three kidneys the change was between 10% and
11% (Table 1).
%ID/cc
The mean %ID/cc (X100) value was 7.88 2.5 (range 4.2 to
12.6) for the first study and 7.57 2.33 (range 4.2 to 12) for the
second study. A good correlation was found between first and
second studies (y = 0.896x + 0.005; r = 0.96). The mean
difference between first and second studies was 0,3 0.69 (range
—0.9 to 1.7), and the mean difference between the first and second
studies as a percentage of the mean value of the two studies was
3.4% 8.1 (range —14.5% to 15%). In 11 kidneys the difference
was less than 5%; in nine kidneys it was between 5% and 9.9% and
in 10 kidneys the change was between 10% and 15% (Table 1).
Uptake
The mean uptake value was 16.4% 3.4% (range 9.7% to
22.7%) for the first study and 15,8% 3.3% (range 9% to 21.5%)
for the second study. A good correlation was found between the
first and second studies (y = 0.91x + 0.89; r = 0.93). The mean
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difference between first and second studies was 0.62% 1.2%
(range —2.9% to 2.5%), and the mean difference between the first
and second studies as a percentage of the mean value of the two
studies was 3.8% 7.1 (range —14.5% to 15%). In 11 kidneys the
difference was less than 5%, in eleven kidneys it was between 5%
and 9.9%, and in 8 kidneys the change was between 10% and 15%
(Table 1).
DISCUSSION
Rather than accurate measurement of the renal function, serial
monitoring of renal function is the major concern in the manage-
ment of patients with renal disease [22—24]. Several radionuclide
techniques have been proposed to evaluate individual kidney
function [4, 8, 22, 24]. The use of radionuclides in the study of the
kidneys relies on their functional ability to provide quantitative
measurement information [23]. The main applications are in the
determination of residual renal function, serial measurements of
renal function when some intervention is planned or monitoring
renal function to detect progressive loss of function [4, 23, 241.
Renal cortical scintigraphy using Tc-DMSA has been used for
detecting renal cortical defects [3, 24—26]. Functional imaging of
the proximal renal tubular mass is obtained that is dependent on
the renal blood flow and proximal tubular cell membrane trans-
port function [8]. The quantitation of Tc-DMSA uptake in each
kidney separately provides a practical index of absolute renal
function [8]. Quantitation of Tc-DMSA uptake by the kidneys
using planar scintigraphy has been reported [9, Ii, 13—18].
However, the need for correction for depth and background limits
the usefulness and prevents widespread acceptance of planar
scintigraphy for quantitation of Tc-DMSA uptake by the individ-
ual kidney [231.
The application of quantitative SPECT of DMSA uptake in the
kidneys to evaluate the individual renal function has been re-
ported [12, 15, 191. Absolute quantitation by SPECT is feasible
and has been shown to be a clinically reliable and useful technique
[12, 19, 27—29]. It can he considered in two levels: measurement of
volumes and measurement of absolute radionuclide concentra-
tions. Thus, QDMSA provides information concerning the per-
cent of injected dose per cc of renal tissue and functional kidney
volumes, and by multiplying these two parameters individual
kidney uptake is obtained. It has been shown that the individual
kidney uptake of DMSA measured by SPECT is useful in
separating normal from diseased kidneys [12]. Also, a good
correlation was found between quantitative SPECT of DMSA
uptake in single kidneys and renal function measured by creati-
nine clearance (r = 0.76) [19] and serum creatinine (r = 0.83 to
0.89) [12, 19], validating the measurements in each kidney sepa-
rately.
In a recent report of the radionuclides in the nephrourology
committee on renal clearance [24], Cr-S 1-EDTA was suggested as
the agent of choice for renal function evaluation. However, this
technique provides information on global renal function, has poor
imaging characteristics and lacks commercial availability [24].
Also, the blood and urine sampling requirements and the length
of the study limit the routine use of these method [22, 24]. In
another recent report on the precision of repeated plasma clear-
ance measurements of Cr-S 1-EDTA on healthy volunteers it was
found that the overall precision of the measurements was 8.4%
[30]. In 9 out of 12 volunteers (75%) the difference between the
first and second measurements was less than 10%, and in the
remaining three volunteers the change was less than 18% [30].
These findings were considered better than those obtained with
any method based on urine samples of inulin or creatinine [301.
In the present report the precision (reproducibility) of QDMSA
was studied. To evaluate the precision of the method, QDMSA
was performed twice with a mean interval of four days apart in
normal volunteers. A precision similar to that obtained with the
plasma clearance of Cr-S 1-EDTA [30] was found when measuring
the QDMSA parameters twice in the same patient. For volume
measurements, 27 out of 30 kidneys (90%) showed less than 10%
difference between the first and second studies, with a precision of
4.8%. For %ID/cc measurements, 20 out of 30 kidneys (67%)
showed less than 10% difference and the remaining 10 kidneys
showed a difference of less than 15% between the first and second
study with an overall precision of 8.1%. For the uptake determi-
nation used as the index of renal function, 22 out of 30 kidneys
(73%) showed less than a 10% difference and the remaining 8
kidneys showed a difference of less than 15% between the first and
second studies, with an overall precision of 7.1%.
In conclusion, quantitative SPECT measurement of Tc-DMSA
uptake by the kidneys is a reproducible method that can reliably
be used to monitor serial changes in individual renal function.
Reprint requests to Dr. D. Groshar, Department of Nuclear Medicine, Bnai
Zion Medical Center, POB 4940, Haifa, Israel, 31048.
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